Rhesus haemolytic disease of the newborn: Postnatal management, associated morbidity and long-term outcome

Seminars in Fetal and Neonatal Medicine

Volumn 13, Issue 4, 2008, Pages 265-271

  Smits Wintjens, V E H J ^a   Walther, F J ^a   Lopriore, E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Exchange transfusion; Management; Phototherapy; Rhesus haemolytic disease of the newborn

Indexed keywords

ALBUMIN; ERYTHROPOIETIN; FOLIC ACID; IMMUNOGLOBULIN; METALLOPORPHYRIN; PHENOBARBITAL;

ANEMIA; ARTICLE; CHOLESTASIS; EXCHANGE BLOOD TRANSFUSION; FETUS HYDROPS; HUMAN; HYPERBILIRUBINEMIA; IRON OVERLOAD; KERNICTERUS; MORBIDITY; NERVOUS SYSTEM DEVELOPMENT; NEWBORN; NEWBORN HEMOLYTIC DISEASE; PHOTOTHERAPY; POSTNATAL CARE; REHYDRATION; THROMBOCYTOPENIA;

ALBUMINS; ANEMIA, NEONATAL; CHOLESTASIS; FLUID THERAPY; HUMANS; HYDROPS FETALIS; HYPERBILIRUBINEMIA, NEONATAL; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; KERNICTERUS; METALLOPORPHYRINS; PHENOBARBITAL; PHOTOTHERAPY; RH ISOIMMUNIZATION; THROMBOCYTOPENIA;

EID: 44949242350     PISSN: 1744165X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.siny.2008.02.005     Document Type: Article

References (70)

1. Bowman J. Thirty-five years of Rh prophylaxis. Transfusion 43 (2003) 1661-1666
2. Stockman III J.A. Overview of the state of the art of Rh disease: history, current clinical management, and recent progress. J Pediatr Hematol Oncol 23 (2001) 385-393
3. Van Kamp I.L., Klumper F.J., Oepkes D., et al. Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization. Am J Obstet Gynecol 192 (2005) 171-177
4. Murray N.A., and Roberts I.A. Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal 92 (2007) F83-F88
5. Greenough A. Rhesus disease: postnatal management and outcome. Eur J Pediatr 158 (1999) 689-693
6. Urbaniak S.J., and Greiss M.A. RhD haemolytic disease of the fetus and the newborn. Blood Rev 14 (2000) 44-61
7. De Boer I., Zeestraten E.C., Lopriore E., Van K.I., Kanhai H.H., and Walther F.J. Pediatric outcome in Rhesus hemolytic disease treated with and without intrauterine transfusion. Am J Obstet Gynecol 198 (2008) 54
8. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 114 (2004) 297-316
9. Hansen T.W. Kernicterus: an international perspective. Semin Neonatol 7 (2002) 103-109
10. Hansen T.W. Mechanisms of bilirubin toxicity: clinical implications. Clin Perinatol 29 (2002) 765-778 viii
11. Mills J.F., and Tudehope D. Fibreoptic phototherapy for neonatal jaundice. Cochrane Database Syst Rev (2001) CD002060
12. Sarici S.U., Alpay F., Unay B., Ozcan O., and Gokcay E. Double versus single phototherapy in term newborns with significant hyperbilirubinemia. J Trop Pediatr 46 (2000) 36-39
13. Stokowski L.A. Fundamentals of phototherapy for neonatal jaundice. Adv Neonatal Care 6 (2006) 303-312
14. Wagner T., Resch B., Reiterer F., Gassner C., and Lanzer G. Pancytopenia due to suppressed hematopoiesis in a case of fatal hemolytic disease of the newborn associated with anti-K supported by molecular K1 typing. J Pediatr Hematol Oncol 26 (2004) 13-15
15. Weiner C.P., and Widness J.A. Decreased fetal erythropoiesis and hemolysis in Kell hemolytic anemia. Am J Obstet Gynecol 174 (1996) 547-551
16. Vaughan J.I., Manning M., Warwick R.M., Letsky E.A., Murray N.A., and Roberts I.A. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmune anemia. N Engl J Med 338 (1998) 798-803
17. Buhot S. Remarks on the clinical prognosis of hemolytic disease of the newborn treated by exchange transfusion. Rev Hematol 5 (1950) 469-470
18. Egberts J., Van Kamp I.L., Kanhai H.H., Meerman R.H., Giordano P.C., and Gravenhorst J.B. The disappearance of fetal and donor red blood cells in alloimmunised pregnancies: a reappraisal. Br J Obstet Gynaecol 104 (1997) 818-824
19. Weiner C.P., Williamson R.A., Wenstrom K.D., et al. Management of fetal hemolytic disease by cordocentesis. II. Outcome of treatment. Am J Obstet Gynecol 165 (1991) 1302-1307
20. Farrant B., Battin M., and Roberts A. Outcome of infants receiving in-utero transfusions for haemolytic disease. N Z Med J 114 (2001) 400-403
21. Keenan W.J., Novak K.K., Sutherland J.M., Bryla D.A., and Fetterly K.L. Morbidity and mortality associated with exchange transfusion. Pediatrics 75 (1985) 417-421
22. Patra K., Storfer-Isser A., Siner B., Moore J., and Hack M. Adverse events associated with neonatal exchange transfusion in the 1990s. J Pediatr 144 (2004) 626-631
23. Jackson J.C. Adverse events associated with exchange transfusion in healthy and ill newborns. Pediatrics 99 (1997) E7
24. Steiner L.A., Bizzarro M.J., Ehrenkranz R.A., and Gallagher P.G. A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality. Pediatrics 120 (2007) 27-32
25. Thayyil S., and Milligan D.W. Single versus double volume exchange transfusion in jaundiced newborn infants. Cochrane Database Syst Rev (2006) CD004592
26. Inglis G.D., and Davies M.W. Prophylactic antibiotics to reduce morbidity and mortality in neonates with umbilical venous catheters. Cochrane Database Syst Rev (2005) CD005251
27. Traen M., Schepens E., Laroche S., and van Overmeire B. Cardiac tamponade and pericardial effusion due to venous umbilical catheterization. Acta Paediatr 94 (2005) 626-628
28. Sinha A., Fernandes C.J., Kim J.J., Fenrich Jr. A.L., and Enciso J. Atrial flutter following placement of an umbilical venous catheter. Am J Perinatol 22 (2005) 275-277
29. Mohan M.S., and Patole S.K. Neonatal ascites and hyponatraemia following umbilical venous catheterization. J Paediatr Child Health 38 (2002) 612-614
30. Kim J.H., Lee Y.S., Kim S.H., Lee S.K., Lim M.K., and Kim H.S. Does umbilical vein catheterization lead to portal venous thrombosis? Prospective US evaluation in 100 neonates. Radiology 219 (2001) 645-650
31. Butler-O'Hara M., Buzzard C.J., Reubens L., McDermott M.P., DiGrazio W., and D'Angio C.T. A randomized trial comparing long-term and short-term use of umbilical venous catheters in premature infants with birth weights of less than 1251 grams. Pediatrics 118 (2006) e25-e35
32. Van Kamp I.L., Klumper F.J., Meerman R.H., Brand A., Bennebroek G.J., and Kanhai H.H. Blood group immunization: results of treatment of fetal anemia with intra-uterine intravascular blood transfusion in the Netherlands, 1987-1995]. Ned Tijdschr Geneeskd 143 (1999) 2527-2531
33. Alpay F., Sarici S.U., Okutan V., Erdem G., Ozcan O., and Gokcay E. High-dose intravenous immunoglobulin therapy in neonatal immune haemolytic jaundice. Acta Paediatr 88 (1999) 216-219
34. Gottstein R., and Cooke R.W. Systematic review of intravenous immunoglobulin in haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal 88 (2003) F6-F10
35. Dagoglu T., Ovali F., Samanci N., and Bengisu E. High-dose intravenous immunoglobulin therapy for rhesus haemolytic disease. J Int Med Res 23 (1995) 264-271
36. Rubo J., and Wahn V. High-dose immunoglobulin therapy of hyperbilirubinemia in rhesus incompatibility. Infusionsther Transfusionsmed 20 Suppl 1 (1993) 104-108
37. Alcock G.S., and Liley H. Immunoglobulin infusion for isoimmune haemolytic jaundice in neonates. Cochrane Database Syst Rev (2002) CD003313
38. Boreus L.O., Jalling B., and Wallin A. Plasma concentrations of phenobarbital in mother and child after combined prenatal and postnatal administration for prophylaxis of hyperbilirubinemia. J Pediatr 93 (1978) 695-698
39. Trolle D. Decrease of total serum-bilirubin concentration in newborn infants after phenobarbitone treatment. Lancet 2 (1968) 705-708
40. Trolle D. Decrease in the mortality rates for low-birth-weight infants after phenobarbitone treatment. Acta Obstet Gynecol Scand 55 (1976) 13-20
41. Valdes O.S., Maurer H.M., Shumway C.N., Draper D.A., and Hossaini A.A. Controlled clinical trial of phenobarbital and-or light in reducing neonatal hyperbilirubinemia in a predominantly Negro population. J Pediatr 79 (1971) 1015-1017
42. Trevett Jr. T.N., Dorman K., Lamvu G., and Moise Jr. K.J. Antenatal maternal administration of phenobarbital for the prevention of exchange transfusion in neonates with hemolytic disease of the fetus and newborn. Am J Obstet Gynecol 192 (2005) 478-482
43. Suresh G.K., Martin C.L., and Soll R.F. Metalloporphyrins for treatment of unconjugated hyperbilirubinemia in neonates. Cochrane Database Syst Rev (2003) CD004207
44. Hansen T.W. Recent advances in the pharmacotherapy for hyperbilirubinaemia in the neonate. Expert Opin Pharmacother 4 (2003) 1939-1948
45. Benders M.J., van Bel F., and van de Bor M. Haemodynamic consequences of phototherapy in term infants. Eur J Pediatr 158 (1999) 323-328
46. Grunhagen D.J., de Boer M.G., de Beaufort A.J., and Walther F.J. Transepidermal water loss during halogen spotlight phototherapy in preterm infants. Pediatr Res 51 (2002) 402-405
47. Maayan-Metzger A., Yosipovitch G., Hadad E., and Sirota L. Transepidermal water loss and skin hydration in preterm infants during phototherapy. Am J Perinatol 18 (2001) 393-396
48. Mehta S., Kumar P., and Narang A. A randomized controlled trial of fluid supplementation in term neonates with severe hyperbilirubinemia. J Pediatr 147 (2005) 781-785
49. al-Alaiyan S., and al Omran A. Late hyporegenerative anemia in neonates with rhesus hemolytic disease. J Perinat Med 27 (1999) 112-115
50. Burk C.D., Malatack J.J., and Ramsey G. Misleading Rh phenotype and severe prolonged anemia in hemolytic disease of the newborn. Am J Dis Child 141 (1987) 712-713
51. Koenig J.M., Ashton R.D., De Vore G.R., and Christensen R.D. Late hyporegenerative anemia in Rh hemolytic disease. J Pediatr 115 (1989) 315-318
52. Millard D.D., Gidding S.S., Socol M.L., et al. Effects of intravascular, intrauterine transfusion on prenatal and postnatal hemolysis and erythropoiesis in severe fetal isoimmunization. J Pediatr 117 (1990) 447-454
53. Aher S., and Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 3 (2006) CD004868
54. Ohlsson A., and Aher S.M. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 3 (2006) CD004863
55. Ovali F., Samanci N., and Dagoglu T. Management of late anemia in Rhesus hemolytic disease: use of recombinant human erythropoietin (a pilot study). Pediatr Res 39 (1996) 831-834
56. Aher S.M., and Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 3 (2006) CD004865
57. Yilmaz S., Duman N., Ozer E., et al. A case of rhesus hemolytic disease with hemophagocytosis and severe iron overload due to multiple transfusions. J Pediatr Hematol Oncol 28 (2006) 290-292
58. Naulaers G., Barten S., Vanhole C., Verhaeghe J., and Devlieger H. Management of severe neonatal anemia due to fetomaternal transfusion. Am J Perinatol 16 (1999) 193-196
59. Segal M., Manning F.A., Harman C.R., and Menticoglou S. Bleeding after intravascular transfusion: experimental and clinical observations. Am J Obstet Gynecol 165 (1991) 1414-1418
60. Saade G.R., Moise Jr. K.J., Copel J.A., Belfort M.A., and Carpenter Jr. R.J. Fetal platelet counts correlate with the severity of the anemia in red-cell alloimmunization. Obstet Gynecol 82 (1993) 987-991
61. Van den Hof M.C., and Nicolaides K.H. Platelet count in normal, small, and anemic fetuses. Am J Obstet Gynecol 162 (1990) 735-739
62. Grobler J.M., and Mercer M.J. Kernicterus associated with elevated predominantly direct-reacting bilirubin. S Afr Med J 87 (1997) 1146
63. Ebbesen F. Low reserve albumin for binding of bilirubin in neonates with deficiency of bilirubin excretion and bronze baby syndrome. Acta Paediatr Scand 71 (1982) 415-420
64. Bertini G., Dani C., Fonda C., Zorzi C., and Rubaltelli F.F. Bronze baby syndrome and the risk of kernicterus. Acta Paediatr 94 (2005) 968-971
65. Ahlfors C.E. Measurement of plasma unbound unconjugated bilirubin. Anal Biochem 279 (2000) 130-135
66. Doyle L.W., Kelly E.A., Rickards A.L., Ford G.W., and Callanan C. Sensorineural outcome at 2 years for survivors of erythroblastosis treated with fetal intravascular transfusions. Obstet Gynecol 81 (1993) 931-935
67. Harper D.C., Swingle H.M., Weiner C.P., Bonthius D.J., Aylward G.P., and Widness J.A. Long-term neurodevelopmental outcome and brain volume after treatment for hydrops fetalis by in utero intravascular transfusion. Am J Obstet Gynecol 195 (2006) 192-200
68. Grab D., Paulus W.E., Bommer A., Buck G., and Terinde R. Treatment of fetal erythroblastosis by intravascular transfusions: outcome at 6 years. Obstet Gynecol 93 (1999) 165-168
69. Hudon L., Moise Jr. K.J., Hegemier S.E., et al. Long-term neurodevelopmental outcome after intrauterine transfusion for the treatment of fetal hemolytic disease. Am J Obstet Gynecol 179 (1998) 858-863
70. Janssens H.M., de Haan M.J., Van Kamp I.L., Brand R., Kanhai H.H., and Veen S. Outcome for children treated with fetal intravascular transfusions because of severe blood group antagonism. J Pediatr 131 (1997) 373-380